Long-term efficacy and safety of prophylactic treatment with recombinant factor IX FC fusion protein (rFIXFc) in subjects with severe or moderate haemophilia B: final longitudinal analysis of B-LONG/kids B-LONG and B-YOND

被引：0
|
作者：
Shapiro, A. D. [1 ]
Kulkarni, R. [2 ]
Ragni, M. V. [3 ]
Mahlangu, J. [4 ,5 ]
Oldenburg, J. [6 ]
Nolan, B. [7 ]
Ozelo, M. C. [8 ]
Willemze, A. [9 ]
Feng, J. [10 ]
Barnowski, C. [10 ]
Barnes, C. [11 ]
机构：
[1] Indiana Hemophilia & Thrombosis Ctr, Indianapolis, IN USA
[2] Michigan State Univ, E Lansing, MI 48824 USA
[3] Univ Pittsburgh, Hemophilia Ctr Western Penn, Pittsburgh, PA USA
[4] Univ Witwatersrand, Haemophilia Comprehens Care Ctr, Fac Hlth Sci, Johannesburg, South Africa
[5] NHLS, Johannesburg, South Africa
[6] Univ Clin Bonn, Inst Expt Haematol & Transfus Med, Bonn, Germany
[7] Our Ladys Childrens Hosp, Dublin, Ireland
[8] Univ Estadual Campinas, Hemoctr UNICAMP, Sao Paulo, Brazil
[9] Sobi, Stockholm, Sweden
[10] Bioverativ, Waltham, MA USA
[11] Royal Childrens Hosp, Melbourne, Vic, Australia
来源：
HAEMOPHILIA | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P009
引用
收藏
页码：39 / 40
页数：2
相关论文
共 50 条
  • [31] Pharmacokinetic parameters of recombinant factor IX Fc fusion protein are not influenced by factor IX antigen levels in subjects from the Phase 3 B-LONG trial
    Sidonio Jr, Robert F.
    Casiano, Sandra
    Falk, Aletta
    Altincatal, Arman
    Katragadda, Suresh
    Santagostino, Elena
    Windyga, Jerzy
    HAEMOPHILIA, 2023, 29 (01) : 404 - 407
  • [32] MAINTENANCE OF HEMOSTASIS IN SUBJECTS UNDERGOING MAJOR SURGERY IN THE PHASE 3 A-LONG AND B-LONG STUDIES OF RECOMBINANT FACTOR VIII AND FACTOR IX FC FUSION PROTEINS
    Powell, Jerry S.
    Klamroth, Robert
    Ozelo, Margaret
    Hermans, Cedric
    Morfini, Massimo
    Mahlangu, Johnny
    Apte, Shahikant
    Robinson, Brian
    Pierce, Glenn F.
    Allen, Geoffrey
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (06) : E92 - E92
  • [33] Maintenance of haemostasis in subjects undergoing major surgery in the phase 3 ALONG and B-LONG studies of recombinant factor VIII and factor IX FC fusion proteins
    Klamroth, R.
    Ozelo, M.
    Mahlangu, J.
    Apte, S.
    Powell, J. S.
    Robinson, B.
    Pierce, G. F.
    Allen, G.
    Hermans, C.
    HAEMOPHILIA, 2014, 20 : 76 - 76
  • [34] Improvement in target joint bleeding during long-term use of recombinant factor IX Fc fusion protein prophylaxis in subjects with haemophilia B
    Pasi, J.
    Kulkarni, R.
    Chambost, H.
    Willemze, A.
    Feng, J.
    Jain, N.
    HAEMOPHILIA, 2019, 25 : 119 - 119
  • [35] Safety, efficacy, and improved pharmacokinetics (PK) demonstrated in a phase 3 clinical trial of extended half-life recombinant FC fusion factor IX (B-LONG)
    Powell, J.
    Ozelo, M.
    Pasi, J.
    Ragni, M.
    Valentino, L.
    Mahlangu, J.
    Josephson, N.
    Perry, D.
    Baker, R.
    Novitzky, N.
    Krassova, S.
    Allen, G.
    Campion, M.
    Jiang, H.
    Li, S.
    Goyal, J.
    Sommer, J.
    Dumont, J.
    Brennan, A.
    Vigliani, G.
    Luk, A.
    Pierce, G.
    HAEMOPHILIA, 2013, 19 : 76 - 77
  • [36] Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A
    Nolan, B.
    Mahlangu, J.
    Perry, D.
    Young, G.
    Liesner, R.
    Konkle, B.
    Rangarajan, S.
    Brown, S.
    Hanabusa, H.
    Pasi, K. J.
    Pabinger, I.
    Jackson, S.
    Cristiano, L. M.
    Li, X.
    Pierce, G. F.
    Allen, G.
    HAEMOPHILIA, 2016, 22 (01) : 72 - 80
  • [37] Dosing intervals and bleeding rates before and following treatment with recombinant factor IXFc fusion protein in patients with severe haemophilia B: experience from the phase 3 B-LONG clinical study
    Negrier, C.
    Powell, J. S.
    Valentino, L. A.
    Robinson, B.
    Potts, J.
    Li, S.
    Jiang, H.
    Allen, G.
    Brennan, A.
    Pierce, G. F.
    HAEMOPHILIA, 2014, 20 : 84 - 85
  • [38] Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B
    Diao, Lei
    Li, Shuanglian
    Ludden, Thomas
    Gobburu, Jogarao
    Nestorov, Ivan
    Jiang, Haiyan
    CLINICAL PHARMACOKINETICS, 2014, 53 (05) : 467 - 477
  • [39] Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B
    Lei Diao
    Shuanglian Li
    Thomas Ludden
    Jogarao Gobburu
    Ivan Nestorov
    Haiyan Jiang
    Clinical Pharmacokinetics, 2014, 53 : 467 - 477
  • [40] Prophylaxis with recombinant factor IX Fc fusion protein reduces the risk of bleeding and delays time to first spontaneous bleed event in previously untreated patients with haemophilia B: A post hoc analysis of the PUPs B-LONG study
    Nolan, Beatrice
    Recht, Michael
    Rendo, Pablo
    Falk, Aletta
    Foster, Meredith
    Casiano, Sandra
    Rauch, Antoine
    Shapiro, Amy
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (04) : 485 - 492
12345